<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Yale J Biol Med</journal-id><journal-id journal-id-type="pmc">yjbm</journal-id><journal-title>The Yale Journal of Biology and Medicine</journal-title><issn pub-type="ppub">0044-0086</issn><issn pub-type="epub">1551-4056</issn><publisher><publisher-name>Yale Journal of Biology and Medicine</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">2479178</article-id><article-id pub-id-type="pmc">2589121</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>The role of interferons in the treatment of malignant neoplasms.</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Murren</surname><given-names>J. R.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Buzaid</surname><given-names>A. C.</given-names></name></contrib></contrib-group><aff>Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut 06510.</aff><pub-date pub-type="ppub"><season>May-Jun</season><year>1989</year></pub-date><volume>62</volume><issue>3</issue><fpage>271</fpage><lpage>290</lpage><abstract><p>Interferons (IFNs) are proteins with a wide range of biological effects. IFNs have antiviral and antiproliferative properties. They modulate both the immune system and the expression of cell phenotype. In the past decade, the IFNs have received intense clinical scrutiny. Alpha IFN is the best studied and displays activity in many neoplastic diseases; it has shown the most promise in the hematological cancers although several solid tumors, including epidemic Kaposi's sarcoma, renal cell carcinoma, and melanoma, respond. No neoplastic disease, however, has been cured by the IFNs. IFN seems to be most active in the setting of minimal residual disease, and clinical studies evaluating its role in the adjuvant setting are under way. Other areas of research include trials combining IFN with cytotoxic drugs or other biological response modifiers, and maintenance IFN to prolong remissions following successful induction therapy.</p></abstract></article-meta></front><body><supplementary-material content-type="scanned-pages"><graphic xlink:href="yjbm00069-0034.tif" xlink:title="scanned-page" xlink:role="271" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="yjbm00069-0035.tif" xlink:title="scanned-page" xlink:role="272" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="yjbm00069-0036.tif" xlink:title="scanned-page" xlink:role="273" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="yjbm00069-0037.tif" xlink:title="scanned-page" xlink:role="274" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="yjbm00069-0038.tif" xlink:title="scanned-page" xlink:role="275" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="yjbm00069-0039.tif" xlink:title="scanned-page" xlink:role="276" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="yjbm00069-0040.tif" xlink:title="scanned-page" xlink:role="277" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="yjbm00069-0041.tif" xlink:title="scanned-page" xlink:role="278" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="yjbm00069-0042.tif" xlink:title="scanned-page" xlink:role="279" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="yjbm00069-0043.tif" xlink:title="scanned-page" xlink:role="280" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="yjbm00069-0044.tif" xlink:title="scanned-page" xlink:role="281" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="yjbm00069-0045.tif" xlink:title="scanned-page" xlink:role="282" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="yjbm00069-0046.tif" xlink:title="scanned-page" xlink:role="283" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="yjbm00069-0047.tif" xlink:title="scanned-page" xlink:role="284" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="yjbm00069-0048.tif" xlink:title="scanned-page" xlink:role="285" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="yjbm00069-0049.tif" xlink:title="scanned-page" xlink:role="286" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="yjbm00069-0050.tif" xlink:title="scanned-page" xlink:role="287" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="yjbm00069-0051.tif" xlink:title="scanned-page" xlink:role="288" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="yjbm00069-0052.tif" xlink:title="scanned-page" xlink:role="289" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="yjbm00069-0053.tif" xlink:title="scanned-page" xlink:role="290" mimetype="image" mime-subtype="tiff"/></supplementary-material></body></article>

